{"entity":{"id":"survive-breast-surveillance","kind":"trial","name":"SURVIVE (intensive versus standard surveillance in early breast cancer)","aka":["SURVIVE"],"tldr":"A large German study asking whether regular blood tests after breast cancer treatment, rather than waiting for symptoms, change what happens to women.","summary":"SURVIVE (NCT05658172) compares standard with intensive surveillance in 3,500 planned patients with early breast cancer; in the intensive arm, abnormal blood results trigger imaging. It is the parent study of SURVIVE HERoes, which randomises patients with HER2-positive or HER2-low disease who have a molecular relapse.","status":"recruiting","asOf":"2026-11-04","links":[{"label":"ClinicalTrials.gov NCT05658172","url":"https://clinicaltrials.gov/study/NCT05658172"}],"tags":[],"related":[],"cancers":["breast-cancer"],"sections":[],"technologies":["mrd-testing","liquid-biopsy"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["mrd","ctdna","tumour-informed-assay"],"trials":["survive-heroes"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT05658172","phase":"not-applicable","setting":"Intermediate- and high-risk early breast cancer after primary treatment: standard surveillance compared with intensive surveillance that adds blood tests (tumour markers, circulating tumour cells and ctDNA)","sponsor":"Prof. Wolfgang Janni","started":"2022-12-07","startedType":"actual","enrolled":3500,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/survive-breast-surveillance/","neighbours":{"cancer":[{"id":"breast-cancer","kind":"cancer","name":"Breast cancer (all types)","route":"/cancers/breast-cancer/"}],"technology":[{"id":"liquid-biopsy","kind":"technology","name":"Liquid biopsy (ctDNA)","route":"/technologies/liquid-biopsy/"},{"id":"mrd-testing","kind":"technology","name":"MRD / molecular residual disease testing","route":"/technologies/mrd-testing/"}],"term":[{"id":"ctdna","kind":"term","name":"Circulating tumour DNA (ctDNA)","route":"/terms/ctdna/"},{"id":"mrd","kind":"term","name":"Minimal / molecular residual disease (MRD)","route":"/terms/mrd/"},{"id":"tumour-informed-assay","kind":"term","name":"Tumour-informed versus tumour-naive ctDNA assays","route":"/terms/tumour-informed-assay/"}],"trial":[{"id":"survive-heroes","kind":"trial","name":"SURVIVE HERoes","route":"/trials/survive-heroes/"}]}}